Antimicrobial Agents for Complicated Skin and Skin‐Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo‐Controlled Trials
- 1 August 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (3), 383-391
- https://doi.org/10.1086/600296
Abstract
Background. The United States Food and Drug Administration requires clinical trial noninferiority margins to preserve a fraction (eg, 50%) of the established comparator drug's efficacy versus placebo. Lack of placebo-controlled trials for many infections complicates noninferiority margin justification for and, hence, regulatory review of new antimicrobial agents. Noninferiority margin clarification is critical to enable new antimicrobial development. In the absence of placebo-controlled trials, we sought to define the magnitude of efficacy of antimicrobial agents and resulting noninferiority margins for studies of complicated skin and skin-structure infection (SSSI). Methods. We systematically reviewed literature on complicated SSSI published during 1900–1950 (before widespread penicillin resistance) to define treatment outcomes and confidence intervals (CIs). Antimicrobial efficacy was calculated as the lower limit CI of the cure rate with antimicrobials minus the upper limit CI of the cure rate without antimicrobials. Results. We identified 90 articles describing >28,000 patients with complicated SSSI. For cellulitis/erysipelas, cure rates were 66% (95% CI, 64%-68%) without antibiotics and 98% (95% CI, 96%-99%) for penicillin-treated patients, and penicillin reduced mortality by 10%. Cure rates for wound/ulcer infections were 36% (95% CI, 32%-39%) without antibiotics and 83% (95% CI, 81%-85%) for penicillin-treated patients. For major abscesses, cure rates were 76% (95% CI, 71%-80%) without antibiotics and 96% (95% CI, 94%-98%) for penicillin-treated patients; penicillin reduced mortality by 6%. Conclusion. Systematic review of historical literature enables rational noninferiority margin justification in the absence of placebo-controlled trials and may facilitate regulatory review of noninferiority trials. Noninferiority margins of 14% for cellulitis/erysipelas, 21% for wound/ulcer infections, and 7% for major abscesses would preserve ⩾50% of antibiotic efficacy versus placebo for these complicated SSSI subsets.Keywords
This publication has 54 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community-Acquired Methicillin-Resistant Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Incidence of Lower-Extremity Cellulitis: A Population-Based Study in Olmsted County, MinnesotaMayo Clinic Proceedings, 2007
- Evidence based medicine - The case of the misleading funnel plotBMJ, 2006
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentThe New England Journal of Medicine, 2006
- Antimicrobial Management of Complicated Skin and Skin Structure Infections in the Era of Emerging ResistanceSurgical Infections, 2005
- Community-Associated MRSA — Resistance and Virulence ConvergeThe New England Journal of Medicine, 2005
- Comparative Merits of Sodium and Procaine PenicillinBMJ, 1949
- Case of Erysipeloid of Rosenbach Treated with PenicillinBMJ, 1949
- PENICILLIN THERAPY IN SCARLET FEVERThe Lancet, 1948
- Topical use of streptomycin in woundsAmerican Journal Of Medicine, 1947